Regeneron Advances First Potential Therapy for Rare Genetic Bone Disorder

Regeneron Pharmaceuticals’ (Regeneron) garetosmab, an investigational monoclonal antibody (mAb) targeting Activin A, holds strong promise to transform treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic bone disorder driving progressive heterotopic ossification (HO). With FDA priority review underway for the company’s biologics license application (BLA) and a target action date of August 2026, approval of this mAb could unlock a first disease-modifying therapy for FOP patients, addressing a critical unmet need in this field.¹

This move by FDA positions Regeneron to capture a pivotal role in the rare disease biologics market, where targeted therapies for HO progression remain scarce.^1,2 FOP is driven by pathogenic variants in the ACVR1 gene that trigger abnormal bone formation within muscles, ligaments, tendons, and connective tissue. Progressive HO leads to irreversible skeletal restriction, loss of mobility, and severe functional impairment affecting breathing, speech, and nutrition. Most individuals become wheelchair dependent by early adulthood, and global diagnosed prevalence remains approximately 900 patients.¹

By targeting Activin A, a signaling protein identified by Regeneron researchers as a central molecular driver of ectopic bone formation in FOP, garetosmab can neutralize the protein and interrupt the downstream osteogenic signaling that is responsible for pathological bone growth.^1,3

How does Activin A inhibition alter disease progression in FOP?

The BLA submission is supported by data from a Phase III trial (OPTIMA), a multinational study evaluating efficacy and safety in adults with active disease. Participants received intravenous garetosmab at doses of 3 mg/kg or 10 mg/kg every four weeks for 56 weeks.

According to the company, both dosing regimens demonstrated substantial reductions in new HO lesion formation compared with placebo. Patients receiving the 3 mg/kg dose experienced a 94% reduction in total new lesions relative to placebo (1 lesion versus 19 lesions; p=0.0274), while the 10 mg/kg cohort achieved a 90% reduction (2 lesions versus 19 lesions; p=0.0260).

Post-hoc analyses further showed greater than 99% reductions in mean total HO lesion volume compared with placebo. These findings suggest potent suppression of the ossification processes that drive the disease and position Activin A blockade as a potential disease-modifying approach, rather than symptomatic management.¹

What does this priority review mean for the development of rare disease biologics?

FDA’s priority review is the latest in the agency’s designations for garetosmab. The mAb previously received fast track and orphan drug designations in the United States, alongside orphan designation in the European Union, reflecting the absence of approved disease-modifying therapies for FOP.

If approved, garetosmab would represent the first therapy shown to reduce both the number and volume of newly formed heterotopic bone lesions in adults with the disorder, according to Regeneron. Sucn an outcome could redefine clinical expectations in genetically driven skeletal diseases.¹

A second Phase III study (OPTIMA 2) is planned to begin later in 2026 that will evaluate garetosmab in pediatric and adolescent patients, expanding investigation of the biologic’s potential in earlier disease intervention.

Garetosmab was generated using Regeneron’s VelocImmune platform, a genetically humanized antibody discovery system that has supported multiple approved mAb therapies. The company’s long-term research into FOP biology contributed to the identification of Activin A signaling as a mechanistic driver of pathological ossification. This identification enabled the company to develop a targeted biologic strategy to address this previously untreatable condition.

The mAb’s safety and efficacy remain under regulatory review and have not yet been fully established by health authorities.

References

1. Regeneron Pharmaceuticals. Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). Press Release. Feb. 19, 2026.
2. Mayo Clinic. A Study Assessing the Efficacy and Safety of 2 Dosage Regimens of Oral IPN60130 for FOP. Accessed Feb. 20, 2026. https://www.mayo.edu/research/clinical-trials/cls-20529870
3. Lin H, Shi F, Gao J, Hua P. The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator. Biosci. Rep. 2019;39(8):BSR20190377. doi: 10.1042/BSR20190377